Literature DB >> 19386475

Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta.

Tomiki Sumiyoshi1, Yuko Higuchi, Toru Itoh, Mie Matsui, Hirofumi Arai, Michio Suzuki, Masayoshi Kurachi, Chika Sumiyoshi, Yasuhiro Kawasaki.   

Abstract

The purpose of this study was to determine if perospirone, a second generation antipsychotic drug and partial agonist at serotonin-5-HT(1A) receptors, enhances electrophysiological activity, such as event-related potentials (ERPs), in frontal brain regions, as well as cognitive function in subjects with schizophrenia. P300 current source images were obtained by means of standardized low resolution brain electromagnetic tomography (sLORETA) before and after treatment with perospirone for 6 months. Perospirone significantly increased P300 current source density in the left superior frontal gyrus, and improved positive symptoms and performance on the script tasks, a measure of verbal social cognition, while verbal learning memory tended to be improved. There was a significant correlation between the changes in P300 amplitude on the left frontal lead and those in social cognition. These results suggest the changes in three-dimensional distribution of cortical activity, as demonstrated by sLORETA, may mediate some of the actions of antipsychotic drugs. The distinct cognition-enhancing profile of perospirone in patients with schizophrenia may be related to its actions on 5-HT(1A) receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386475     DOI: 10.1016/j.pscychresns.2008.07.005

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

1.  Prolonged P300 Latency in Antipsychotic-Free Subjects with At-Risk Mental States Who Later Developed Schizophrenia.

Authors:  Yuko Higuchi; Tomiki Sumiyoshi; Takahiro Tateno; Suguru Nakajima; Daiki Sasabayashi; Shimako Nishiyama; Yuko Mizukami; Tsutomu Takahashi; Michio Suzuki
Journal:  J Pers Med       Date:  2021-04-21

Review 2.  Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?

Authors:  Wilhelmina A M Vingerhoets; Oswald J N Bloemen; Geor Bakker; Therese A M J van Amelsvoort
Journal:  Front Psychiatry       Date:  2013-12-04       Impact factor: 4.157

3.  Mismatch negativity and p3a/reorienting complex in subjects with schizophrenia or at-risk mental state.

Authors:  Yuko Higuchi; Tomonori Seo; Tomohiro Miyanishi; Yasuhiro Kawasaki; Michio Suzuki; Tomiki Sumiyoshi
Journal:  Front Behav Neurosci       Date:  2014-05-13       Impact factor: 3.558

4.  On the use of the P300 as a tool for cognitive processing assessment in healthy aging: A review.

Authors:  Sofia Cristina Iost Pavarini; Allan Gustavo Brigola; Bruna Moretti Luchesi; Érica Nestor Souza; Estefani Serafim Rossetti; Francisco José Fraga; Letícia Pimenta Costa Guarisco; Marélli Terassi; Nathalia Alves Oliveira; Priscilla Hortense; Renata Valle Pedroso; Ana Carolina Ottaviani
Journal:  Dement Neuropsychol       Date:  2018 Jan-Mar

Review 5.  Electrophysiological Evidence in Schizophrenia in Relation to Treatment Response.

Authors:  Kazuki Sueyoshi; Tomiki Sumiyoshi
Journal:  Front Psychiatry       Date:  2018-06-13       Impact factor: 4.157

6.  A systematic review of the effects of psychiatric medications on social cognition.

Authors:  Zoë Haime; Andrew J Watson; Nadia Crellin; Louise Marston; Eileen Joyce; Joanna Moncrieff
Journal:  BMC Psychiatry       Date:  2021-11-29       Impact factor: 3.630

7.  LORETA current source density for duration mismatch negativity and neuropsychological assessment in early schizophrenia.

Authors:  Tomohiro Miyanishi; Tomiki Sumiyoshi; Yuko Higuchi; Tomonori Seo; Michio Suzuki
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

8.  Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.

Authors:  Yuko Higuchi; Tomiki Sumiyoshi; Tomonori Seo; Tomohiro Miyanishi; Yasuhiro Kawasaki; Michio Suzuki
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

Review 9.  Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia.

Authors:  Tomiki Sumiyoshi; Yuko Higuchi; Takashi Uehara
Journal:  Front Behav Neurosci       Date:  2013-10-16       Impact factor: 3.558

10.  s-SMOOTH: Sparsity and Smoothness Enhanced EEG Brain Tomography.

Authors:  Ying Li; Jing Qin; Yue-Loong Hsin; Stanley Osher; Wentai Liu
Journal:  Front Neurosci       Date:  2016-11-28       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.